Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT05177796 2024-10-24

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2 Withdrawn

Breast

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02067416 2023-02-02

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT04762901 2022-04-26

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT04038489 2021-11-22

Breast 51

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03634150 2021-10-26

Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Phase 1/2 Withdrawn

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03285607 2018-08-16

MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT01227408 2017-05-02

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT02637375 2016-05-30

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Phase NA Withdrawn

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02215876 2016-04-15

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT02053597 2015-09-17

TRIUMPH

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT00022230 2015-05-05

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Phase 1/2 Withdrawn

Breast

Breast Neoplasms

NCT00074139 2014-03-05

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT01159236 2012-07-31

Molecular Triaging of Newly Diagnosed Breast Cancer

Phase NA Withdrawn

Breast

Breast Neoplasms

NCT01333423 2012-06-26

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1 Withdrawn

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT00006261 2010-06-10

Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

Clinical Trials

MK-5890-003

TNBC

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Breast 51

Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer

TRIUMPH

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer

Molecular Triaging of Newly Diagnosed Breast Cancer

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer